French pharmaceutical giant Sanofi-Aventis Group Inc. failed in federal court to stop a publisher from using the name of its yet-to-be-approved obesity drug in a news website’s address.
Eager to brandish its coast-to-coast credentials in intellectual property litigation, Philadelphia’s Duane Morris is quickly building a national platform by hiring laterals from competing firms across the U.S.
A federal judge has granted Abbott Laboratories Inc.’s request for a preliminary injunction against Ranbaxy Laboratories Ltd. and Andrx Corp. over its antibiotic Biaxin XL.
A plea bargain by a former expert witness could whip up a storm for Milberg Weiss, amid allegations of kickbacks to lead plaintiffs by the firm that paved the way for the modern securities class-action industry.
Drug maker Novartis AG’s acquisition of Chiron Corp. will expand the Swiss company’s footprints in the U.S. biotech market even as its generics division braces for a battle to launch the first generic biotech drugs in the United States.
Investors took legal action against drug maker Andrx Corp. Tuesday, accusing the pharmaceutical company of violating federal securities laws and misrepresenting the approval status of new drug applications with the U.S. Food and Drug Administration.
After filing a new suit earlier this week, Biovail Laboratories now has two patent infringement lawsuits pending against Andrx Pharmaceuticals in the same court over the same drug.
Generic drug maker Alphapharm Pty Ltd. must steer clear of blockbuster antidepressant Lexapro for now as part its settlement agreement with Forest Laboratories Inc., ending litigation launched in May 2004.
Managed healthcare company AmeriGroup Corporation is facing a class-action lawsuit from purchasers of its common stock for allegedly withholding damaging financial results during a five-month period to mislead investors.
In a case that could end up costing Johnson & Johnson millions more, a federal jury has ruled that the health-care products giant knowingly infringed a patent held by two Florida doctors and ordered the company to pay the breast cancer specialists $2 million.
Israeli drug maker Teva Pharmaceutical Industries Ltd. is seeking to produce a generic version of the schizophrenia drug Seroquel, which garnered drug originator AstraZeneca $2 billion in worldwide sales last year.
Belgian drugmaker UCB Societe Anonyme has sued IVAX Corporation in federal court, seeking protection of its popular epilepsy drug Keppra from generic competition before the expiration of its patent.
Toyota’s hybrid Prius has been drawing attention from consumers and patent holding companies alike, with yet another small transmission company asserting an obscure patent against the car maker.
Automaker Toyota’s increasingly popular hybrid vehicles are under fire for patent infringement, with a boutique electric motor manufacturer asserting its prized electric-wheel patent in Florida district court Monday.
California-based Alza Corporation, a maker of drugs for attention disorders, has filed a complaint against two domestic rivals over their attempts to gain approval for generic versions of its drug Concerta.
A federal appeals court has reinstated part of an antitrust challenge to a deal between Irish drug maker Elan and Skyepharma over a generic version of the non-steroidal anti-inflammatory drug Naprelan (naproxen sodium).
Asserting its patent for a feature of Internet shopping, a Virginia-based company sued Texas computer technology giant Dell among others.
J2 Global Communications has sued two more companies in its widening litigation over patent rights to digital faxing and messaging.
A popular drug for controlling blood pressure is at the center of a new patent lawsuit brought by Biovail Laboratories against generics maker Andrx Pharmaceuticals.
Yahoo Inc. won an $8 million settlement from online advertising company Miva Inc. Monday, ending three-year-old patent litigation around the automated placement of ads online.